SEBI Reg. Investment Advisor

Download App

MoneyWorks4Me

Sun Pharma slips as its arm voluntarily withdraws 28 ANDAs in US

20 Dec 2016 Evaluate

Sun Pharmaceutical Industries is currently trading at Rs. 627.35, down by 4.85 points or 0.77% from its previous closing of Rs. 632.20 on the BSE.

The scrip opened at Rs. 633.00 and has touched a high and low of Rs. 638.00 and Rs. 625.00 respectively. So far 197453 shares were traded on the counter.

The BSE group 'A' stock of face value Rs. 1 has touched a 52 week high of Rs. 898.00 on 23-Feb-2016 and a 52 week low of Rs. 572.40 on 09-Nov-2016.

Last one week high and low of the scrip stood at Rs. 693.00 and Rs. 625.00 respectively. The current market cap of the company is Rs. 150651.78 crore.

The promoters holding in the company stood at 54.97%, while Institutions and Non-Institutions held 33.34% and 11.68% respectively.

Sun Pharmaceutical Industries’ one of the wholly-owned subsidiaries has voluntarily requested the US Food and Drug Administration (USFDA) to withdraw approval for 28 Abbreviated New Drug Applications (ANDAs). These older drug products belong to erstwhile Ranbaxy Laboratories and are not being marketed in the US since 2008.

The pharma major had recently concluded the acquisition of 100% stake of Ocular Technologies, Sarl (OTS), a portfolio company of Auven Therapeutics (Auven), on December 15, 2016. OTS owns exclusive, worldwide rights to Seciera (cyclosporine A, 0.09% ophthalmic solution).

Sun Pharmaceutical Industries is a pharmaceuticals company. The company's business segments include US Business, Indian Branded Generics Business, Emerging Markets, Global Consumer Healthcare Business and Active Pharmaceutical Ingredients (API).

 

Sun Pharma Inds. Share Price

1847.30 12.90 (0.70%)
08-May-2026 16:59 View Price Chart
Peers
Company Name CMP
Sun Pharma Inds. 1847.30
Dr. Reddys Lab 1293.25
Cipla 1347.70
Zydus Lifesciences 938.90
Lupin 2377.90
View more..

About MoneyWorks4Me

MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.

Our Vision

To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.

What Makes MoneyWorks4Me Different

Our Approach: Ensuring compounding work its magic on client portfolio.

MoneyWorks4Me ensures this through:

×